CD8A and urothelial carcinoma: For example, in the phase III IMvigor210 trial evaluating atezolizumab for urothelial carcinoma, patients with high CGB-family gene expression exhibited markedly reduced CD8+ T-cell infiltration and significantly shorter overall survival, indicating that these tumors are intrinsically less responsive to immune-checkpoint inhibition (42, 45).